305 related articles for article (PubMed ID: 21430030)
1. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
Gomberg SJ; Wustrack RL; Napoli N; Arnaud CD; Black DM
J Clin Endocrinol Metab; 2011 Jun; 96(6):1627-32. PubMed ID: 21430030
[TBL] [Abstract][Full Text] [Related]
2. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
Huang HT; Kang L; Huang PJ; Fu YC; Lin SY; Hsieh CH; Chen JC; Cheng YM; Chen CH
Menopause; 2012 Dec; 19(12):1360-3. PubMed ID: 22968250
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.
Panico A; Lupoli GA; Marciello F; Lupoli R; Cacciapuoti M; Martinelli A; Granieri L; Iacono D; Lupoli G
Med Sci Monit; 2011 Aug; 17(8):CR442-448. PubMed ID: 21804463
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful?
Tarazona-Santabalbina FJ; Aguilella-Fernández L
Aging Clin Exp Res; 2013 Oct; 25(5):605-9. PubMed ID: 24026625
[TBL] [Abstract][Full Text] [Related]
5. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
[TBL] [Abstract][Full Text] [Related]
6. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
7. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
Kwek EB; Goh SK; Koh JS; Png MA; Howe TS
Injury; 2008 Feb; 39(2):224-31. PubMed ID: 18222447
[TBL] [Abstract][Full Text] [Related]
8. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
Miller PD; McCarthy EF
Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
[TBL] [Abstract][Full Text] [Related]
10. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
11. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide.
Carvalho NN; Voss LA; Almeida MO; Salgado CL; Bandeira F
J Clin Endocrinol Metab; 2011 Sep; 96(9):2675-80. PubMed ID: 21752890
[TBL] [Abstract][Full Text] [Related]
12. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
[TBL] [Abstract][Full Text] [Related]
13. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
[TBL] [Abstract][Full Text] [Related]
14. Atypical femoral fracture after long-term alendronate treatment: report of a case evidenced with magnetic resonance imaging.
Kao CM; Huang PJ; Chen CH; Chen SJ; Cheng YM
Kaohsiung J Med Sci; 2012 Oct; 28(10):555-8. PubMed ID: 23089322
[TBL] [Abstract][Full Text] [Related]
15. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Angthong C; Angthong W
J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S214-20. PubMed ID: 22619933
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
Body JJ; Gaich GA; Scheele WH; Kulkarni PM; Miller PD; Peretz A; Dore RK; Correa-Rotter R; Papaioannou A; Cumming DC; Hodsman AB
J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
[TBL] [Abstract][Full Text] [Related]
18. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
19. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy.
Capeci CM; Tejwani NC
J Bone Joint Surg Am; 2009 Nov; 91(11):2556-61. PubMed ID: 19884427
[TBL] [Abstract][Full Text] [Related]
20. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
Marcus R; Wang O; Satterwhite J; Mitlak B
J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]